HealthEquity에 대한 매도 수량은 투자자에게 HealthEquity의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

HealthEquity (NASDAQ:HQY) 주식, 공매도 수량 보고

HealthEquity

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

APTO

MOMO

SPWH

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 헬로 그룹(NASDAQ:MOMO)이 개장 전에 3억 7,252만 달러의 매출과 주당 28센트의 분기 이익을 보고할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면, 헬로 그룹의 주가는 시간외 거래에서 0.6% 하락한 6.60달러를 기록했다.

화요일 주목해야 할 주식: 헬로 그룹, Z스케일러, 앱토즈 그리고 2종목

Health Care

Movers

헬스에퀴티(NASDAQ:HQY)는 회사가 월요일 1분기 재무 결과를 발표한 후 주가가 상승했다. 이 보고서의 주요 내용을 살펴보자. 중요한 사항 (The Details): 헬스에퀴티는 분기별 주당 이익을 80센트로 보고했는데, 이는 애널리스트들의 합의 추정치인 66센트를 21.21% 상회했으며, 지난해 같은 기간보다 주당 이익인 50센트보다 60% 증가한 수치이다.

헬스에퀴티: 예상보다 좋은 제1분기 실적과 강력한 전망 발표 후 주가 상승

ADSK

LVRO

SAIC

YGMZ

월요일 아침(현지 시간) 미국 주식 선물이 상승면서, 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: Benzinga Pro의 데이터에 따르면 월스트리트는 사이언스 애플리케이션 인터내셔널(NYSE:SAIC)가 개장 전에 분기별 이익을 주당 1.92달러, 매출 18억 4천만 달러로 보고할 것으로 예상하고 있다. SAIC 주식은 시간외 거래에서 3.4% 상승한 139.20달러를 기록했다. 

사이언스 애플리케이션, 오토데스크 그리고 월요일 주목해야 할 주식 3종목

HealthEquity Inc

<p>According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.</p>
<p>Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.</p>
<p>The report attributed this to increased use of medications for obesity and diabetes.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a></strong></p>
<p>The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.</p>
<p>Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.</p>
<p>Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.</p>
<p>Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.</p>
<p>Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.</p>
<p>Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.</p>
<p>The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></strong></li>
</ul>
<p><em>Photo by MargJohnsonVA via Shutterstock</em></p>


Biotech

Government

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

WIIM

Health Equity shares are trading lower after the company reported worse-than-expected Q3 sales results.

<p>JMP Securities  analyst Constantine Davides   maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Market Outperform and raises the price target from $105 to $107.</p>


Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on HealthEquity, Raises Price Target to $107

<p>RBC Capital  analyst Sean Dodge   maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $100 to $105.</p>


RBC Capital Maintains Outperform on HealthEquity, Raises Price Target to $105

<p>U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.</p>
<p>Shares of <strong>Yext, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) fell sharply in today's pre-market trading after reporting <a href="https://www.benzinga.com/quote/YEXT">third-quarter results</a>.</p>
<p>Yext reported quarterly earnings of 12 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $114.000 million which beat the analyst consensus estimate of $113.208 million.</p>
<p>Yext shares dipped 10.8% to $7.60 in the pre-market trading session.</p>
<p>Here are some other stocks moving lower in pre-market trading.</p>
<ul>
<li><strong>Huize Holding Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUIZ#NASDAQ">HUIZ</a>) shares fell 18.4% to $4.93 in pre-market trading after reporting third-quarter results.</li>
<li><strong>Radiopharm Theranostics Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares dipped 18.4% to $7.42 in pre-market trading after dipping 51% on Monday.</li>
<li><strong>UP Fintech Holding Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) shares dipped 9.4% to $7.04 in pre-market trading after jumping 26% on Monday.</li>
<li><strong>Fluence Energy, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) shares fell 8.8% to $16.90 in pre-market trading. The company announced a senior convertible notes offering amounting to $300 million with an option for an additional $45 million.</li>
<li><strong>Bilibili Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares fell 8.5% to $21.24 in pre-market trading.</li>
<li><strong>HarborOne Bancorp, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HONE#NASDAQ">HONE</a>) shares fell 7.8% to $12.00 in pre-market trading.</li>
<li><strong>Oracle Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares dipped 7.2% to $176.80 in pre-market trading as the company posted weaker-than-expected earnings and sales results for its second quarter.</li>
<li><strong>HealthEquity, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) fell 6% to $95.00 in pre-market trading after the company reported worse-than-expected third-quarter sales results.</li>
<li><strong>Lufax Holding Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LU#NASDAQ">LU</a>) declined 5.5% to $2.76 in pre-market trading.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/12/42405361/sp-500-nasdaq-retreat-from-record-highs-investor-sentiment-declines-fear-greed-index-remains-in-neutral-zone">S&amp;P 500, Nasdaq Retreat From Record Highs As Nvidia Declines Over Chinese Antitrust Concerns: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></strong></li>
</ul>


BILI

FLNC

HONE

HUIZ

ORCL

RADX

TIGR

YEXT

Yext, Oracle, Huize Holding And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<p>The Q3 earnings report for <strong>HealthEquity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) was released on Monday, December 9, 2024 at 04:01 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.</p>
<p>Revenue was up $51.21 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>The company beat on EPS by $0.16 in the last quarter, resulting in a 5.0% increase share price change the following day.</p>
<p>Here's a look at HealthEquity's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.</p>
<p>To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into HealthEquity Q3 Earnings

<p><strong>HealthEquity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) announced its Q3 earnings on Monday, December 9, 2024 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.</p>
<p>Revenue was up $51.21 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.16, leading to a 5.0% increase share price change the next day.</p>
<p>Here's a look at HealthEquity's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.</p>
<p>To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: HealthEquity Q3

<p><strong>HealthEquity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) announced its Q3 earnings on Monday, December 9, 2024 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.</p>
<p>Revenue was up $51.21 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.16 in the last quarter, resulting in a 5.0% increase share price change the following day.</p>
<p>Here's a look at HealthEquity's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.</p>
<p>To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HealthEquity Earnings Analysis: Q3 Recap

<p><strong>HealthEquity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) announced its Q3 earnings on Monday, December 9, 2024 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.</p>
<p>Revenue was up $51.21 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat on EPS by $0.16 which was followed by a 5.0% increase in the share price the next day.</p>
<p>Here's a look at HealthEquity's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.</p>
<p>To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: HealthEquity Q3

<p>The Q3 earnings report for <strong>HealthEquity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) was released on Monday, December 9, 2024 at 04:01 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.</p>
<p>Revenue was up $51.21 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>Last quarter the company beat on EPS by $0.16 which was followed by a 5.0% increase in the share price the next day.</p>
<p>Here's a look at HealthEquity's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.</p>
<p>To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HealthEquity Q3 Earnings Assessment

Health Equity shares are trading lower after the company reported worse-than-expected Q3 sales results,

Guidance

Health Equity Sees FY26 Revenue $1.275B-$1.295B.

<p>The earnings results for <strong>HealthEquity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) for Q3 were made public on Monday, December 9, 2024 at 04:01 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.</p>
<p>Revenue was up $51.21 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company beat on EPS by $0.16, leading to a 5.0% increase share price change the next day.</p>
<p>Here's a look at HealthEquity's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HealthEquity Earnings Report: Q3 Overview

HealthEquity Sees FY25 Adj. EPS $3.08-$3.16 vs $3.11 Est; Revenue $1.185B-$1.195B Vs $1.184B Est.

<p>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.74 by 5.41 percent.  The company reported quarterly sales of $300.400 million which missed the analyst consensus estimate of $305.343 million by 1.62 percent.  This is a 20.54 percent increase over sales of $249.219 million the same period last year.</p>


Earnings Beats

Earnings Misses

HealthEquity Q3 2025 Adj. EPS $0.78 Beats $0.74 Estimate, Sales $300.400M Miss $305.343M Estimate

<h3>Companies Reporting Before The Bell</h3>
<p>• Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) is likely to report quarterly loss at $4.45 per share on revenue of $76.05 million. </p>
<p>• VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is projected to report quarterly earnings at $0.41 per share on revenue of $29.20 million. </p>
<p>• Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $366.41 million. </p>
<h3>Companies Reporting After The Bell</h3>
<p>• Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) is projected to report quarterly earnings at $4.27 per share on revenue of $4.02 billion. </p>
<p>• Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) is estimated to report quarterly earnings at $4.34 per share on revenue of $3.17 billion. </p>
<p>• MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) is likely to report quarterly earnings at $0.69 per share on revenue of $495.72 million. </p>
<p>• Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) is likely to report quarterly loss at $4.98 per share on revenue of $251.62 million. </p>
<p>• Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) is projected to report quarterly loss at $0.11 per share on revenue of $9.03 million. </p>
<p>• Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is projected to report quarterly loss at $0.29 per share on revenue of $106.00 million. </p>
<p>• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is expected to report quarterly earnings at $0.72 per share on revenue of $290.00 million. </p>
<p>• Amtech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASYS#NASDAQ">ASYS</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $23.75 million. </p>
<p>• Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) is likely to report quarterly earnings at $1.48 per share on revenue of $14.11 billion. </p>
<p>• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is projected to report quarterly loss at $0.01 per share on revenue of $148.19 million. </p>
<p>• Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is projected to report quarterly earnings at $0.12 per share on revenue of $113.21 million. </p>
<p>• C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) is expected to report quarterly loss at $0.16 per share on revenue of $91.02 million. </p>
<p>• Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is likely to report quarterly loss at $0.04 per share on revenue of $63.12 million. </p>
<p>• Oil-Dri Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODC#NYSE">ODC</a>) is projected to report earnings for its first quarter. </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ASYS

BRZE

CASY

GNSS

RENT

VBNK

Earnings Scheduled For December 9, 2024

<p>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is preparing to release its quarterly earnings on Monday, 2024-12-09. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect HealthEquity to report an <strong>earnings per share</strong> (EPS) of $0.71.</p>
<p>HealthEquity bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.16, leading to a 5.13% increase in the share price the following trading session.</p>
<p>Here's a look at HealthEquity's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733493625_0_0.png" alt="eps graph" /></p>
<h3>Market Performance of HealthEquity's Stock</h3>
<p>Shares of HealthEquity were trading at $100.845 as of December 05. Over the last 52-week period, shares are up 42.32%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on HealthEquity</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on HealthEquity.</p>
<p>Analysts have provided HealthEquity with 6 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $118.17, suggesting a potential 17.18% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Alignment Healthcare, Clover Health Investments and Progyny, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Alignment Healthcare is favoring an Buy trajectory, with an average 1-year price target of $12.5, suggesting a potential 87.6% downside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Clover Health Investments, with an average 1-year price target of $4.0, implying a potential 96.03% downside.</li>
<li>The consensus among analysts is an Neutral trajectory for Progyny, with an average 1-year price target of $21.0, indicating a potential 79.18% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Alignment Healthcare, Clover Health Investments and Progyny, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HealthEquity</td>
<td>Outperform</td>
<td>23.15%</td>
<td>$204.05M</td>
<td>1.68%</td>
</tr>
<tr>
<td>Alignment Healthcare</td>
<td>Buy</td>
<td>51.61%</td>
<td>$78.99M</td>
<td>-22.17%</td>
</tr>
<tr>
<td>Clover Health Investments</td>
<td>Neutral</td>
<td>8.16%</td>
<td>$81.21M</td>
<td>-2.74%</td>
</tr>
<tr>
<td>Progyny</td>
<td>Neutral</td>
<td>2.04%</td>
<td>$59.24M</td>
<td>2.34%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>HealthEquity ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity.</p>
<h3>Get to Know HealthEquity Better</h3>
<p>HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.</p>
<h3>Key Indicators: HealthEquity's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> HealthEquity displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately <strong>23.15%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> HealthEquity's net margin excels beyond industry benchmarks, reaching <strong>11.94%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> HealthEquity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1.68%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> HealthEquity's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.06%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.54</strong>, HealthEquity adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/HQY/earnings"><strong>To track all earnings releases for HealthEquity visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into HealthEquity's Upcoming Earnings

<p>Mizuho  analyst Steven Valiquette   initiates coverage on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform rating and announces Price Target of $126.</p>


Initiation

Mizuho Initiates Coverage On HealthEquity with Outperform Rating, Announces Price Target of $126

<p>In the last three months, 10 analysts have published ratings on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $108.8, with a high estimate of $130.00 and a low estimate of $92.00. This current average has increased by 5.41% from the previous average price target of $103.22. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733162434_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive HealthEquity. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>David Larsen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$103.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to HealthEquity. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into HealthEquity's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HQY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on HealthEquity analyst ratings.</strong></a></p>
<h2>Delving into HealthEquity's Background</h2>
<p>HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.</p>
<h3>HealthEquity's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> HealthEquity displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately <strong>23.15%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> HealthEquity's net margin excels beyond industry benchmarks, reaching <strong>11.94%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> HealthEquity's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.68%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.06%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> HealthEquity's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.54</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For HealthEquity

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>JP Morgan raised the price target for <strong>Affirm Holdings, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) from $56 to $74. JP Morgan analyst Reginald Smith maintained an Overweight rating. Affirm shares closed at $70.01 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Tigress Financial boosted the price target for <strong>T-Mobile US, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) from $235 to $280. Tigress Financial analyst Ivan Feinseth maintained a Buy rating. Kohl&#8217;s shares closed at $246.94 on Friday. <a href="https://www.benzinga.com/quote/TMUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research boosted <strong>HealthEquity, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) price target from $105 to $120. Barrington Research analyst Alexander Paris maintained an Outperform rating. HealthEquity shares settled at $101.54 on Friday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital boosted <strong>Emerson Electric Co</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) price target from $130 to $155. Loop Capital analyst Chris Dankert maintained a Buy rating. Emerson Electric shares closed at $132.60 on Friday. <a href="https://www.benzinga.com/quote/EMR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group raised <strong>Netflix, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) price target from $775 to $950. Evercore ISI Group analyst Mark Mahaney maintained an Outperform rating. Netflix shares closed at $886.81 on Friday.  <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted <strong>Flywire Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) price target from $23 to $26. Deutsche Bank analyst Nate Svensson maintained a Buy rating on the stock. Flywire shares closed at $22.71 on Friday. See how other analysts view this stock.</li>
<li>UBS cut the price target for <strong>Applied Therapeutics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) from $13 to $2. UBS analyst Esther Rajavelu downgraded the stock from Buy to Neutral. Applied Therapeutics shares settled at $2.03 on Friday. <a href="https://www.benzinga.com/quote/APLT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities boosted <strong>Citigroup Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) price target from $78 to $90. B of A Securities analyst Ebrahim Poonawala maintained a Buy rating. Citigroup shares closed at $70.87 on Friday. <a href="https://www.benzinga.com/quote/C/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein increased the price target for <strong>Block, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) from $90 to $120. Bernstein analyst Harshita Rawat maintained an Outperform rating. Block shares closed at $88.55 on Friday. <a href="https://www.benzinga.com/quote/SQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank cut <strong>Dell Technologies Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) price target from $144 to $142. Deutsche Bank analyst Sidney Ho maintained a Buy rating. Dell shares closed at $127.59 on Friday. <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p><strong>Read This Next:</strong></p>
<ul>
<li><strong> <a href="https://www.benzinga.com/top-stories/24/12/42265024/how-to-earn-500-a-month-from-marvell-technology-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Marvell Technology Stock Ahead Of Q3 Earnings</a></strong></li>
</ul>


AFRM

APLT

DELL

FLYW

NFLX

TMUS

Netflix To Rally More Than 7%? Here Are 10 Top Analyst Forecasts For Monday

JMP Securities raised the firm's price target on HealthEquity (HQY) to $107 from $105 and keeps an Outperform rating on the shares. HealthEquity re...

HealthEquity price target raised to $107 from $105 at JMP Securities

RBC Capital analyst Sean Dodge raised the firm's price target on HealthEquity (HQY) to $105 from $100 and keeps an Outperform rating on the shares....

HealthEquity price target raised to $105 from $100 at RBC Capital

Analyst Alexander Paris of Barrington reiterated a Buy rating on Healthequity (HQY – Research Report), reducing the price target to $112.00. Alexan...

HealthEquity's Strong Q3 Performance and Revised Guidance Justify Buy Rating

Barrington analyst Alexander Paris lowered the firm's price target on HealthEquity (HQY) to $112 from $120 and keeps an Outperform rating on the sh...

HealthEquity price target lowered to $112 from $120 at Barrington

Healthequity Inc (HQY) has disclosed a new risk, in the Corporate Activity and Growth category. Healthequity Inc. is poised to undergo a critical l...

Leadership Change at Healthequity Inc.: Challenges and Risks as Scott Cutler Steps In as CEO

Bank of America Securities analyst Allen Lutz has reiterated their bullish stance on HQY stock, giving a Buy rating yesterday. Allen Lutz's rating ...

Positive Outlook for HealthEquity Amid Conservative Guidance and Market Expansion Opportunities

Allspring SMID Cap Growth Fund Q3 2024 Commentary

Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on HQY stock, giving a Buy rating yesterday. Steven Valiquette has ...

Healthequity's Strong Performance and Promising Outlook Justifies Buy Rating

J.P. Morgan analyst Anne Samuel maintained a Buy rating on Healthequity (HQY – Research Report) on December 16 and set a price target of $110.00. T...

Comments

HealthEquity

매도 수량

HealthEquity (NASDAQ:HQY) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌